Novo Nordisk drops as GLP-1 headwinds prompt guidance cut

11 hours ago 1

Earnings News
Healthcare
On the Move

Novo Nordisk office in Fremont, California, USA

Novo Nordisk (NVO) ADRs lost ~15% in the premarket on Tuesday after the Danish drugmaker lowered its full-year outlook, citing, among other things, pressure on its obesity drug franchise led by its GLP-1 medication semaglutide.

Eli Lilly (LLY), its

Recommended For You

Read Entire Article

Novo Nordisk drops as GLP-1 headwinds prompt guidance cut

Recommended For You

Related

PotlatchDeltic anticipates Q3 adjusted EBITDDA to rise signi...

Clearwater Paper outlines $1.5B–$1.6B revenue target for 202...

NMI Holdings signals ongoing $25M quarterly share repurchase...

Camden National signals cost synergy acceleration with Q3 no...

COPT Defense Properties raises 2025 FFO per share guidance a...

Excelerate Energy hikes full-year EBITDA guidance to reflect...

Teladoc Health in charts: U.S. revenue continues to decline ...

Starbucks in charts: Global comparable store sales declines ...

Ares Capital signals potential for increased investing volum...

Teradyne up 4% after bottom line quarterly beat, issuing Q3 ...

TPG RE Finance Trust GAAP EPS of $0.21 beats by $0.03

BTCS files prospectus for resale of 5M shares by existing st...

Gold could hit $4,000 by end of 2026, Fidelity says

DexCom Q2 2025 Earnings Preview

LendingClub stock surges after Q2 beat, strong Q3 guidance

Avis shares slip as mixed Q2 results highlight soft U.S. ren...

SoFi Technologies announces public offering of common stock

Kilroy Realty files automatic mixed securities shelf

PPG reports Q2 earnings in line with estimates; revenue tops...

Hammond Manufacturing declares $0.03 dividend

Trending

Popular

تصاویر سیمینِ زیبای شکارگاه در پشت‌صحنه

رمزارز امسال در بورس کالا عرضه می‌شود